Cheng-Xian Guo
Overview
Explore the profile of Cheng-Xian Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Yu B, Peng Y, Mou K, Zhan Y, Wang Y, et al.
Innovation (Camb)
. 2025 Feb;
6(2):100773.
PMID: 39991480
Pharmacogenomic landscapes and related databases are important for identifying the biomarkers of drug response and toxicity. However, these data are still lacking for the Chinese population. In this study, we...
2.
Mei J, Jiang X, Tian H, Rong D, Song J, Wang L, et al.
MedComm (2020)
. 2024 Sep;
5(10):e718.
PMID: 39286778
The extracellular matrix (ECM) governs a wide spectrum of cellular fate processes, with a particular emphasis on anoikis, an integrin-dependent form of cell death. Currently, anoikis is defined as an...
3.
Liu K, Zhang Y, Yin H, Yu L, Cui J, Yin J, et al.
Microbes Infect
. 2023 Sep;
26(1-2):105228.
PMID: 37734532
It has recently been found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) m6A modifications can affect viral replication and function. However, no studies to date have shown a correlation...
4.
Yu L, Hu B, Huang H, Yu B, Xiao Q, Lv Q, et al.
J Transl Med
. 2023 Jan;
21(1):11.
PMID: 36624463
Background: Radiotherapy (RT) is the standard treatment for nasopharyngeal carcinoma (NPC). However, due to individual differences in radiosensitivity, biomarkers are needed to tailored radiotherapy to cancer patients. However, comprehensive genome-wide...
5.
Wang Y, Xiao F, Zhao Y, Mao C, Yu L, Wang L, et al.
Mol Cancer
. 2022 Aug;
21(1):169.
PMID: 35999636
Background: Genetic variants associated with acute side effects of radiotherapy in nasopharyngeal carcinoma (NPC) remain largely unknown. Methods: We performed a two-stage genome-wide association analysis including a total of 1084...
6.
Wang L, Cui J, Ouyang Q, Zhan Y, Wang Y, Xu X, et al.
EPMA J
. 2021 Jul;
12(3):307-324.
PMID: 34306260
Aims: Coronavirus disease 2019 (COVID-19) is rapidly spreading worldwide. Drug therapy is one of the major treatments, but contradictory results of clinical trials have been reported among different individuals. Furthermore,...
7.
Wang L, Cui J, Ouyang Q, Zhan Y, Guo C, Yin J
Lancet
. 2020 Oct;
396(10256):953-954.
PMID: 33010833
No abstract available.
8.
Guo C, He L, Yin J, Meng X, Tan W, Yang G, et al.
BMC Med
. 2020 Aug;
18(1):250.
PMID: 32762696
Background: COVID-19 is an extremely severe infectious disease. However, few studies have focused on the epidemiological and clinical characteristics of pediatric COVID-19. This study conducted a retrospective review of the...
9.
Wang M, Kuang Y, Gong L, Hua Y, Pei Q, Guo C, et al.
Invest New Drugs
. 2020 Jun;
38(6):1826-1835.
PMID: 32535812
We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects...
10.
Huang J, Liu W, Yu J, Yang J, Li M, Zou C, et al.
Br J Clin Pharmacol
. 2020 Apr;
86(11):2225-2233.
PMID: 32333407
Aims: To determine deficiencies in the Food and Drug Administration (FDA)'s guidance for assessing acarbose bioequivalence (BE) and to explore optimal pharmacodynamic (PD) metrics for better evaluation of acarbose BE....